EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma

Ching-Tso Chen iD, Chien-Huai Chuang iD, Chih-Hung Hsu, Yu-Yun Shao iD

Journal of Hepatocellular Carcinoma · 2025-10 · Volume 12 · 2341-2349

DOI: 10.2147/jhc.s548785 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2025-10. Verfasst von Ching-Tso Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: Early alpha-fetoprotein (AFP) response has been reported to predict the treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced hepatocellular carcinoma (HCC). We evaluated the predictive value of another HCC tumor marker, protein induced by vitamin K absence/antagonists-II (PIVKA-II).

Methods

We prospectively established a cohort of advanced HCC patients who received ICI treatment at two medical centers. Serum PIVKA-II levels were obtained before and within 4 weeks after treatment initiation. Any decline in serum PIVKA-II levels was defined as an early PIVKA-II response. Treatment response, overall survival (OS), and progression-free survival (PFS) were compared between patients with and without an early PIVKA-II response.

Results

In total, 67 patients were included; liver reserve was Child-Pugh class A in all patients and albumin-bilirubin grade 1 in 67.2% of the patients. An early PIVKA-II response, which was observed in 19 (28.4%) patients, was associated with a higher objective response rate (50.0% vs 16.4%, p = 0.002). Patients with an early PIVKA-II response had superior OS (median 34.3 vs 13.7 months, p = 0.015) and PFS (median 8.4 vs 4.0 months, p = 0.049) compared with those without a response. In multivariate analysis, an early PIVKA-II response remained an independent predictor for longer OS (p = 0.012) and PFS (p = 0.044). An early PIVKA-II response can complement an early AFP response in predicting prognosis.

Conclusion

An early PIVKA-II response is predictive of tumor response and superior survival outcomes in patients who received ICIs for advanced HCC. PIVKA-II is an emerging tumor marker for HCC, widely used in diagnosis and prognostic stratification. Early PIVKA-II response, defined as any decline of serum PIVKA-II level within 4 weeks after initiation of ICIs treatment, may predict treatment efficacy for patients with advanced HCC.

Schlagwörter

Stichwörter der Autor:innen

DCPPD-L1 blockadePIVKA-IIdes-γ-carboxy prothrombinimmunotherapyprotein induced by vitamin K absence/antagonists-II

Autor:innen und Institutionen

  • Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
  • Department of Oncology, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu, Taiwan.
  • Graduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.

ORCID-Profile: Ching-Tso Chen, Chien-Huai Chuang, Yu-Yun Shao

Zitieren

APA

Chen, C. T., Chuang, C. H., Hsu, C. H., & Shao, Y. Y. (2025). Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma, Volume 12, 2341-2349. https://doi.org/10.2147/jhc.s548785

Vancouver

Chen CT, Chuang CH, Hsu CH, Shao YY. Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. 2025;Volume 12:2341-2349. doi:10.2147/jhc.s548785

BibTeX
@article{Chen2025,
  author = {Chen, Ching-Tso and Chuang, Chien-Huai and Hsu, Chih-Hung and Shao, Yu-Yun},
  title = {Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma},
  journal = {Journal of Hepatocellular Carcinoma},
  year = {2025},
  volume = {Volume 12},
  pages = {2341--2349},
  doi = {10.2147/jhc.s548785}
}
Kostenlos starten →